Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks
Public ClinicalTrials.gov record NCT00168103. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Human Pasteurized C1 Esterase Inhibitor Concentrate (CE1145) in Subjects With Congenital C1-INH Deficiency and Acute Abdominal or Facial HAE Attacks
Study identification
- NCT ID
- NCT00168103
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- CSL Behring
- Industry
- Enrollment
- 126 participants
Conditions and interventions
Conditions
Interventions
- C1 Esterase Inhibitor Biological
- Placebo Biological
Biological
Eligibility (public fields only)
- Age range
- 6 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2005
- Primary completion
- Sep 30, 2007
- Completion
- Nov 30, 2007
- Last update posted
- Mar 30, 2015
2005 – 2007
United States locations
- U.S. sites
- 17
- U.S. states
- 17
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Study Site | Granada Hills | California | 91344 | — |
| Study Site | Weston | Florida | 33331 | — |
| Study Site | Atlanta | Georgia | 30342 | — |
| Study Site | Idaho Falls | Idaho | 83404 | — |
| Study Site | Chicago | Illinois | 60612 | — |
| Study Site | Shreveport | Louisiana | 71130 | — |
| Study Site | Boston | Massachusetts | 02115 | — |
| Study Site | Plymouth | Minnesota | 55411 | — |
| Study Site | Omaha | Nebraska | 68131 | — |
| Study Site | The Bronx | New York | 10461 | — |
| Study Site | Cincinnati | Ohio | 45231 | — |
| Study Site | Tulsa | Oklahoma | 74133 | — |
| Study Site | Eugene | Oregon | 97401 | — |
| Study Site | Hershey | Pennsylvania | 17033 | — |
| Study Site | Rapid City | South Dakota | 57702 | — |
| Study Site | Dallas | Texas | 75230 | — |
| Study Site | Bellingham | Washington | 98225 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00168103, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 30, 2015 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00168103 live on ClinicalTrials.gov.